[go: up one dir, main page]

UA94622C2 - Kinase innhibitor - Google Patents

Kinase innhibitor

Info

Publication number
UA94622C2
UA94622C2 UAA200903417A UAA200903417A UA94622C2 UA 94622 C2 UA94622 C2 UA 94622C2 UA A200903417 A UAA200903417 A UA A200903417A UA A200903417 A UAA200903417 A UA A200903417A UA 94622 C2 UA94622 C2 UA 94622C2
Authority
UA
Ukraine
Prior art keywords
innhibitor
kinase
prodrugs
compound
solvates
Prior art date
Application number
UAA200903417A
Other languages
English (en)
Ukrainian (uk)
Inventor
Тимоти А. ГИЛЛЕСПИ
Пол Эйнотт
Элизабет М. АЛЛЕН
Кин Т. Ю
Эшер ЗИЛБЕРСТЕЙН
Original Assignee
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Авентис filed Critical Санофи-Авентис
Publication of UA94622C2 publication Critical patent/UA94622C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Данное изобретение касается соединения формулы (I):(I)и пролекарств, фармацевтически приемлемых солей или сольватов таких соединений и их пролекарств. Такое соединение имеет полезные фармацевтические свойства, в частности способность ингибировать протеинкиназы.
UAA200903417A 2006-09-11 2007-11-09 Kinase innhibitor UA94622C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82516806P 2006-09-11 2006-09-11

Publications (1)

Publication Number Publication Date
UA94622C2 true UA94622C2 (en) 2011-05-25

Family

ID=39032357

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200903417A UA94622C2 (en) 2006-09-11 2007-11-09 Kinase innhibitor

Country Status (32)

Country Link
US (2) US8658649B2 (ru)
EP (1) EP2094708B1 (ru)
JP (1) JP5161237B2 (ru)
KR (1) KR101443056B1 (ru)
CN (2) CN103804383A (ru)
AR (1) AR062745A1 (ru)
AU (1) AU2007296592B8 (ru)
BR (1) BRPI0716781A2 (ru)
CA (1) CA2663175C (ru)
CL (1) CL2007002617A1 (ru)
CO (1) CO6160236A2 (ru)
CR (1) CR10636A (ru)
DK (1) DK2094708T3 (ru)
ES (1) ES2437318T3 (ru)
GT (1) GT200900055A (ru)
HN (1) HN2009000455A (ru)
IL (1) IL197381A (ru)
MA (1) MA30781B1 (ru)
MX (1) MX2009002616A (ru)
MY (1) MY148107A (ru)
NI (1) NI200900021A (ru)
NO (1) NO20091265L (ru)
NZ (1) NZ575496A (ru)
PE (1) PE20081372A1 (ru)
PT (1) PT2094708E (ru)
RU (1) RU2440352C2 (ru)
TN (2) TN2009000050A1 (ru)
TW (1) TWI399379B (ru)
UA (1) UA94622C2 (ru)
UY (1) UY30584A1 (ru)
WO (1) WO2008033798A2 (ru)
ZA (1) ZA200901073B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2713324A1 (en) * 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
CN101952294B (zh) 2008-02-25 2014-11-26 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
CN101939324B (zh) 2008-02-25 2014-10-15 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
CN101945877B (zh) 2008-02-25 2013-07-03 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
AU2009218609A1 (en) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
NZ587906A (en) * 2008-03-10 2011-12-22 Sanofi Aventis Treatment for ocular-related disorders
FR2929851B1 (fr) 2008-04-09 2012-11-30 Centre Nat Rech Scient Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
PA8851701A1 (es) 2008-12-03 2010-07-27 Sanofi Aventis Tratamiento para la glomerulonefritis
WO2010065690A1 (en) * 2008-12-04 2010-06-10 Sanofi-Aventis Crystalline forms
AR074776A1 (es) * 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
US20110112101A1 (en) * 2009-03-05 2011-05-12 Sanofi-Aventis Treatment for ocular-related disorders
AR075869A1 (es) * 2009-03-19 2011-05-04 Sanofi Aventis Sintesis de azaindoles
PT2516434E (pt) 2009-12-23 2015-10-05 Takeda Pharmaceutical Pirrolidinonas heteroaromáticas fundidas como inibidores de syk
US8481541B2 (en) * 2010-03-22 2013-07-09 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
TWI496785B (zh) 2010-05-20 2015-08-21 Hoffmann La Roche 吡咯并吡激酶抑制劑
CN103003281A (zh) * 2010-05-20 2013-03-27 弗·哈夫曼-拉罗切有限公司 作为JAK和SYK抑制剂的吡咯并[2，3-b]吡嗪-7-甲酰胺衍生物和它们的用途
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
EP2723739B1 (en) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
JP6404215B2 (ja) * 2012-08-21 2018-10-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｓｙｋ阻害剤としてのピロロ［２，３−ｂ］ピラジン
JP6159028B2 (ja) * 2013-07-31 2017-07-05 ギリアード サイエンシーズ， インコーポレイテッド Ｓｙｋ阻害剤
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN116969927B (zh) * 2023-06-07 2024-03-19 中南民族大学 一种从荜茇中提取分离的化合物及该化合物在制备抗炎药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1141949A (en) 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
US3992392A (en) 1973-04-27 1976-11-16 The Ohio State University Research Foundation Synthesis of indoles from anilines and intermediates therein
SE9100920D0 (sv) 1991-03-27 1991-03-27 Astra Ab New active compounds
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
JPH10510510A (ja) 1994-06-09 1998-10-13 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体拮抗物質
FR2732969B1 (fr) 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2215242T3 (es) 1996-11-19 2004-10-01 Amgen Inc. Agentes antiinflamatorios de pirrol condensado sustituido con arilo y heteroarilo.
US6312835B1 (en) 1997-02-13 2001-11-06 Queen's University At Kingston Luminescent compounds and methods of making and using same
IL131582A0 (en) 1997-03-19 2001-01-28 Basf Ag Pyrrolo [2,3d] pyrimidines and their use as tyrosine kinase inhibitors
WO1998047899A1 (en) 1997-04-24 1998-10-29 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
TR200000333T2 (tr) 1997-08-05 2000-05-22 Pfizer Products Inc. Y alıcı antagonistleri olarak 4-aminopirol (3,2-d) pirimidinler.
KR100378937B1 (ko) 1997-10-20 2003-05-09 에프. 호프만-라 로슈 아게 바이사이클릭 키나아제 억제제
JP4741725B2 (ja) 1998-03-06 2011-08-10 メタベイシス・セラピューティクス・インコーポレーテッド リン含有化合物のための新規なプロドラッグ
AU3210799A (en) 1998-04-02 1999-10-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1999051596A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1999061436A1 (en) 1998-05-26 1999-12-02 Chugai Seiyaku Kabushiki Kaisha Heterocyclic indole derivatives and mono- or diazaindole derivatives
CZ2001959A3 (cs) 1998-09-18 2001-12-12 Basf Aktiengesellschaft 4-Aminopyrrolopyrimidiny jako inhibitory kinasy
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB9930698D0 (en) * 1999-12-24 2000-02-16 Rhone Poulenc Rorer Ltd Chemical compounds
HK1050191B (en) 1999-12-24 2011-04-29 Aventis Pharma Limited Azaindoles
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
DE10009000A1 (de) 2000-02-25 2001-08-30 Basf Ag Verfahren zur Herstellung substituierter Indole
AU2001247589A1 (en) 2000-03-20 2001-10-03 Axys Pharmaceuticals, Inc. Non-amidine containing protease inhibitors
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US6673923B2 (en) 2000-05-03 2004-01-06 Tularik Inc. Pyrazole antimicrobial agents
WO2001096336A2 (en) 2000-06-14 2001-12-20 Warner-Lambert Company 6,5-fused bicyclic heterocycles
CA2424222A1 (en) 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
IL161576A0 (en) 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
US20040082365A1 (en) * 2002-07-18 2004-04-29 Celerica Ltd Digitization and transmitting cellular RF signals by several light wavelengths
EP1388541A1 (en) 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
WO2006015124A2 (en) * 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
FR2876582B1 (fr) 2004-10-15 2007-01-05 Centre Nat Rech Scient Cnrse Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
JP2008519036A (ja) 2004-11-08 2008-06-05 バクスター・インターナショナル・インコーポレイテッド チューブリン阻害化合物のナノ粒子組成物
EP2316835A1 (en) * 2004-11-22 2011-05-04 Vertex Pharmceuticals Incorporated Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
US20110112101A1 (en) 2009-03-05 2011-05-12 Sanofi-Aventis Treatment for ocular-related disorders

Also Published As

Publication number Publication date
CN103804383A (zh) 2014-05-21
CA2663175C (en) 2012-03-13
UY30584A1 (es) 2008-05-02
MA30781B1 (fr) 2009-10-01
CO6160236A2 (es) 2010-05-20
NI200900021A (es) 2010-01-29
AU2007296592B8 (en) 2012-01-12
DK2094708T3 (da) 2014-01-27
CN101511838A (zh) 2009-08-19
AR062745A1 (es) 2008-12-03
CA2663175A1 (en) 2008-03-20
IL197381A0 (en) 2009-12-24
GT200900055A (es) 2010-07-28
EP2094708B1 (en) 2013-10-23
JP2010502767A (ja) 2010-01-28
MY148107A (en) 2013-02-28
PT2094708E (pt) 2014-01-07
RU2440352C2 (ru) 2012-01-20
JP5161237B2 (ja) 2013-03-13
AU2007296592B2 (en) 2011-12-15
NO20091265L (no) 2009-04-03
KR20090063214A (ko) 2009-06-17
TN2009000049A1 (en) 2010-08-19
CL2007002617A1 (es) 2008-05-16
TW200829590A (en) 2008-07-16
US8658649B2 (en) 2014-02-25
BRPI0716781A2 (pt) 2014-11-18
ZA200901073B (en) 2009-12-30
WO2008033798A2 (en) 2008-03-20
PE20081372A1 (es) 2008-11-27
US20140142110A1 (en) 2014-05-22
TWI399379B (zh) 2013-06-21
TN2009000050A1 (en) 2010-08-19
RU2009113615A (ru) 2010-10-20
US20100035884A1 (en) 2010-02-11
WO2008033798A3 (en) 2008-05-15
EP2094708A2 (en) 2009-09-02
MX2009002616A (es) 2009-03-24
AU2007296592A1 (en) 2008-03-20
NZ575496A (en) 2011-09-30
CR10636A (es) 2009-03-20
KR101443056B1 (ko) 2014-09-22
IL197381A (en) 2013-11-28
ES2437318T3 (es) 2014-01-10
HN2009000455A (es) 2012-02-13

Similar Documents

Publication Publication Date Title
UA94622C2 (en) Kinase innhibitor
MX2010004263A (es) Inhibidores de quinasa c-fms.
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
MX2009011579A (es) Pirimidinonas como moduladores de caseina cinasa ii (ck2).
PH12012502057A1 (en) Compounds for inhibiting mitotic progression
MY148634A (en) Pyridazinone derivatives
TNSN08191A1 (en) Kinase inhibitors
MX2009002010A (es) Derivados de heteroarilo como inhibidores de la proteina cinasa.
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
WO2009016460A8 (en) Pyrazole compounds and their use as raf inhibitors
MX2009005604A (es) Inhibidores espiro cetona de acetil-coa carboxilasa.
TW200800990A (en) Azaindole inhibitors of aurora kinases
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
SE0400284D0 (sv) Novel compounds
PL1761520T3 (pl) Inhibitory kinazy
TNSN08529A1 (en) Inhibitors of akt (protein kinase b)
TN2010000038A1 (en) Organic compounds
IL219643A0 (en) Kinase inhibitors and methods of use thereof
MX2011012629A (es) Inhibidores de actividad de cinasa tipo pirimidina.
MX2007013624A (es) Inhibidores de proteina cinasa.
WO2008086128A3 (en) Aminopyrazole kinase inhibitors
TNSN08242A1 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof